How Has the Clinical Biomarkers Market Size Evolved in Recent Years?
The clinical biomarkers market has seen considerable growth due to a variety of factors.
•In recent times, the clinical biomarkers market has expanded remarkably. The market value is projected to rise from $30.78 billion in 2024 to $33.85 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%.
The historical growth can be associated with the rising occurrence of chronic diseases, the emphasis on personalized medicine and targeted therapies, advancements in drug development and clinical trials, along with regulatory backing and funding.
What are the Market Size and Expected Growth Rates for the Clinical Biomarkers Market?
The clinical biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations suggest a swift expansion of the clinical biomarkers market in the coming years with estimations reaching $52.8 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.8%.
The surge during the forecast period is likely due to the enlargement of companion diagnostics, an emphasis on preliminary diagnosis and disease prevention, and rising use in precision oncology and neurodegenerative diseases, not to mention the increase in infectious diseases. The forecast period is also set to see predominant trends like AI-facilitated biomarker discovery, inclusion of machine learning, multi-omics integration, technological advancements, and strategic alliances between key players.
Which Drivers Are Accelerating Growth In The Clinical Biomarkers Market?
The expansion of the clinical biomarker market is predicted to be driven by the widespread presence of cancer. Cancer, often described as a group of disorders where abnormal cells multiply uncontrollably with the likelihood of harming healthy tissue, is prevalent. Clinical biomarkers are instrumental in thwarting cancer as they assist with early detection, risk evaluation, and tracking of those particularly susceptible to developing cancer. For instance, as per the UK-based Cancer Research UK, a rise in the new kidney cancer cases is foreseen between 2023 and 2025, from roughly 16,300 initially to about 21,900 by 2038–2040, marking a 15% surge within that time. Hence, the high occurrence rate of cancer is accelerating the growth of the clinical biomarker market.
What Are The Core Segments Of The Global Clinical Biomarkers Market?
The clinical biomarkers market covered in this report is segmented –
1) By Offering: Product, Service
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), Other Technologies
3) By Clinical Area: Cancer Biomarker, Cardiac Biomarker, Neurological Biomarker, Infectious Disease Biomarker, Immunological Biomarker, Non-Invasive Prenatal Testing, Other Clinical Areas
4) By Application: Clinical Diagnostic, Translational Research
5) By End User: Contract Research Organizations (CROs), Research And Academic Laboratories, Biopharmaceutical And Biotech Companies, Diagnostic Centers, Other End Users
Subsegments:
1) By Product: Diagnostic Kits, Reagents, Assay Kits, Instruments
2) By Service: Biomarker Discovery Services, Analytical Services, Clinical Trial Services, Data Analysis Services
Pre-Book The Clinical Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Clinical Biomarkers Market Size?
Advancements in technology are becoming a significant trend in the clinical biomarker industry. To stay ahead in the market, key businesses in the clinical biomarker industry are inventing cutting-edge technologies. For instance, Veravas Inc., an American pharmaceutical manufacturer, introduced the VeraBIND (Biomarker Isolation and N-enrichment for Detection) technology in June 2023. This technology offers a unique and comprehensive method that boosts the accuracy of biomarker identification and minimizes the risk of false positives or negatives in various sample types. By utilizing this innovation, clinical laboratories can enhance their diagnostic procedures and support early detection of diseases, facilitating timely and targeted interventions. Furthermore, VeraBIND technology expedites the creation of assays, resulting in precision and consistency in research, clinical trials, and diagnostic screenings.
Who Are the Key Players in the Clinical Biomarkers Market?
Major companies operating in the clinical biomarkers market include:
• Johnson and Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Danaher Corporation
• Merck KGaA
• Becton Dickinson and Company
• Eurofins Scientific
• Agilent Technologies Inc.
• Epigenomics AG
• Grifols S.A.
• Illumina Inc.
• BioMerieux SA.
• Charles River Laboratories International Inc.
• PerkinElmer Inc.
• Sartorius AG
• Sysmex Corporation
• Waters Corporation
• Bio-Rad Laboratories Inc.
• Bruker Corporation
• Qiagen N.V.
• Myriad Genetics Inc.
• Luminex Corporation
• Veracyte Inc.
• Centogene N.V.
• NanoString Technologies Inc.
• Enzo Biochem Inc.
• Biocartis Group NV
• Agendia Inc.
• Siemens Healthcare Private Limited.
What are the Regional Insights into the Clinical Biomarkers Market?
North America was the largest region in the clinical biomakers market in 2024. The regions covered in the clinical biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
